Rate control in asthma — GPhC CRA MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Diltiazem modified-release after prescriber assessment
A rate-limiting calcium-channel blocker may be preferred when beta-blocker therapy is unsuitable due to asthma. The best answer addresses the key safety, legal or pharmaceutical care issue in the vignette. The other options would either delay appropriate care, create a new risk, or fail to resolve the issue. This is consistent with the cited UK reference for safe pharmacy practice.
Reference: BNF; NICE CKS